Latest Cell signaling Stories
TOKYO and SAN DIEGO, March 12, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. Astellas has exercised its right to terminate the worldwide license agreement signed in 2009, and over the months ahead the companies will work...
Some 5.8 million Americans suffer from heart failure, a currently incurable disease. But scientists at Temple University School of Medicine's (TUSM) Center for Translational Medicine have discovered a key biochemical step underlying the condition that could aid the development of new drugs to treat and possibly prevent it. "Drugs we currently use for heart failure are not very effective," explained lead investigator Walter J. Koch, PhD, Professor and Chairman of the Department of...
Prediction of over 45 million protein kinase-substrate interactions now available at PhosphoNET website VANCOUVER, March 6, 2013 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world-leader in molecular intelligence research, announced a major upgrade in its PhosphoNET KnowledgeBase (www.phosphonet.ca) for the study of cell communication systems. This open-access website now features data on over 177,000 experimentally-confirmed human phosphorylation sites (P-sites) and...
Innovative collaboration launched with ConfometRx, the GPCR structural biology company founded by Stanford University professor and Nobel Prize winner Brian Kobilka PALO ALTO, Calif., Feb. 21, 2013 /PRNewswire-USNewswire/ -- ConfometRx announced today that it has sealed a research agreement with UCB to enable the discovery of novel medicines addressing unmet medical need in Neuroscience. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to...
Lee Rannals for redOrbit.com – Your Universe Online One new method may be able to lead to more effective medications, with fewer side effects, according to research published in the Journal of Neuroscience. Scientists from the University of Texas Medical Branch (UTMB) at Galveston and the University of Houston found a new way to influence the vital serotonin signaling system. The team linked malfunctions in serotonin signaling to a range of health issues, including everything from...
New Study Advances Leading-Edge Field of Optogenetics at Rensselaer Polytechnic Institute and UC Berkeley A new study from engineers at Rensselaer Polytechnic Institute and the University of California, Berkeley, pairs light and genetics to give researchers a powerful new tool for manipulating cells. Results of the study, published in the journal Nature Methods, show how blue light can be used as a switch to prompt targeted proteins to accumulate into large clusters. This process of...
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Senesco Technologies, Inc. (OTCQB: SNTI) today announced that Leslie J. Brown, Ph.D., CEO & President, will present at RetailInvestorConferences.com. DATE: February 7, 2013 TIME: 1:00 PM EST LINK: www.retailinvestorconferences.com > red "register / watch event now" button This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as...
Scientists at the Center for Translational Medicine at the Temple University School of Medicine are inching closer to solving a long-standing mystery in sepsis, a complex and often life-threatening condition that affects more than 400,000 people in the U.S. every year. By blocking the activity of a protein, STIM1, in cells that line the insides of blood vessels in mice, they have halted a cascade of cellular events that culminates in the out-of-control inflammation that marks sepsis, and...
Brett Smith for redOrbit.com - Your Universe Online After numerous research studies raised questions over its safety, several states and countries began banning the sale of products containing bisphenol A (BPA), prompting companies in the plastics industry to begin producing products that were “BPA free.” However, a new study from the University of Texas Medical Branch at Galveston (UTMB) shows that a widely used BPA substitute, bisphenol S (BPS), has the same negative effect as the...
SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its proprietary Cellular Redistribution Assay (CRA) technology, which to date has successfully "unlocked" 46 of the 80 total Class A orphan G Protein-Coupled Receptors (GPCRs) for drug development, has identified small molecules that interact with a Class B GPCR. Like the Class A GPCRs, Class B receptors are important players in a broad range of disorders, having been linked to various...
